Global Vaccin Antirabic Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Rabies vaccine is a vaccine to prevent the occurrence of rabies.The vaccine is very good at preventing wound infection.It can be divided into two types: one is post-exposure (bite, scratch) prevention, and the other is pre-exposure (no bite, scratch) prevention.
LPI (LP Information)' newest research report, the “Vaccin Antirabic Industry Forecast” looks at past sales and reviews total world Vaccin Antirabic sales in 2022, providing a comprehensive analysis by region and market sector of projected Vaccin Antirabic sales for 2023 through 2029. With Vaccin Antirabic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccin Antirabic industry.
This Insight Report provides a comprehensive analysis of the global Vaccin Antirabic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccin Antirabic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vaccin Antirabic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccin Antirabic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccin Antirabic.
The global Vaccin Antirabic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Vaccin Antirabic players cover GSK, Sanofi, Chengda, Yisheng, Merck, VACN, Changsheng, BCHT and Hissen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccin Antirabic market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Vaccin Antirabic market?
What factors are driving Vaccin Antirabic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccin Antirabic market opportunities vary by end market size?
How does Vaccin Antirabic break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Rabies vaccine is a vaccine to prevent the occurrence of rabies.The vaccine is very good at preventing wound infection.It can be divided into two types: one is post-exposure (bite, scratch) prevention, and the other is pre-exposure (no bite, scratch) prevention.
LPI (LP Information)' newest research report, the “Vaccin Antirabic Industry Forecast” looks at past sales and reviews total world Vaccin Antirabic sales in 2022, providing a comprehensive analysis by region and market sector of projected Vaccin Antirabic sales for 2023 through 2029. With Vaccin Antirabic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccin Antirabic industry.
This Insight Report provides a comprehensive analysis of the global Vaccin Antirabic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccin Antirabic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vaccin Antirabic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccin Antirabic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccin Antirabic.
The global Vaccin Antirabic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Vaccin Antirabic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Vaccin Antirabic players cover GSK, Sanofi, Chengda, Yisheng, Merck, VACN, Changsheng, BCHT and Hissen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccin Antirabic market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Gopher Kidney Cell Vaccine
- Freeze-Dried Vero Cell Vaccine
- Common Vero Cell Vaccines
- Human Diploid Vaccine
- Pre-exposure Prophylaxis
- After Exposure Prophylaxis
- Additional Doses
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Sanofi
- Chengda
- Yisheng
- Merck
- VACN
- Changsheng
- BCHT
- Hissen
- Zhongke Biological
- Ningbo Rongan Biological Pharmaceutical
- Guangzhou Nuocheng Biological
What is the 10-year outlook for the global Vaccin Antirabic market?
What factors are driving Vaccin Antirabic market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccin Antirabic market opportunities vary by end market size?
How does Vaccin Antirabic break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccin Antirabic Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Vaccin Antirabic by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Vaccin Antirabic by Country/Region, 2018, 2022 & 2029
2.2 Vaccin Antirabic Segment by Type
2.2.1 Gopher Kidney Cell Vaccine
2.2.2 Freeze-Dried Vero Cell Vaccine
2.2.3 Common Vero Cell Vaccines
2.2.4 Human Diploid Vaccine
2.3 Vaccin Antirabic Sales by Type
2.3.1 Global Vaccin Antirabic Sales Market Share by Type (2018-2023)
2.3.2 Global Vaccin Antirabic Revenue and Market Share by Type (2018-2023)
2.3.3 Global Vaccin Antirabic Sale Price by Type (2018-2023)
2.4 Vaccin Antirabic Segment by Application
2.4.1 Pre-exposure Prophylaxis
2.4.2 After Exposure Prophylaxis
2.4.3 Additional Doses
2.5 Vaccin Antirabic Sales by Application
2.5.1 Global Vaccin Antirabic Sale Market Share by Application (2018-2023)
2.5.2 Global Vaccin Antirabic Revenue and Market Share by Application (2018-2023)
2.5.3 Global Vaccin Antirabic Sale Price by Application (2018-2023)
3 GLOBAL VACCIN ANTIRABIC BY COMPANY
3.1 Global Vaccin Antirabic Breakdown Data by Company
3.1.1 Global Vaccin Antirabic Annual Sales by Company (2018-2023)
3.1.2 Global Vaccin Antirabic Sales Market Share by Company (2018-2023)
3.2 Global Vaccin Antirabic Annual Revenue by Company (2018-2023)
3.2.1 Global Vaccin Antirabic Revenue by Company (2018-2023)
3.2.2 Global Vaccin Antirabic Revenue Market Share by Company (2018-2023)
3.3 Global Vaccin Antirabic Sale Price by Company
3.4 Key Manufacturers Vaccin Antirabic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccin Antirabic Product Location Distribution
3.4.2 Players Vaccin Antirabic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VACCIN ANTIRABIC BY GEOGRAPHIC REGION
4.1 World Historic Vaccin Antirabic Market Size by Geographic Region (2018-2023)
4.1.1 Global Vaccin Antirabic Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Vaccin Antirabic Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Vaccin Antirabic Market Size by Country/Region (2018-2023)
4.2.1 Global Vaccin Antirabic Annual Sales by Country/Region (2018-2023)
4.2.2 Global Vaccin Antirabic Annual Revenue by Country/Region (2018-2023)
4.3 Americas Vaccin Antirabic Sales Growth
4.4 APAC Vaccin Antirabic Sales Growth
4.5 Europe Vaccin Antirabic Sales Growth
4.6 Middle East & Africa Vaccin Antirabic Sales Growth
5 AMERICAS
5.1 Americas Vaccin Antirabic Sales by Country
5.1.1 Americas Vaccin Antirabic Sales by Country (2018-2023)
5.1.2 Americas Vaccin Antirabic Revenue by Country (2018-2023)
5.2 Americas Vaccin Antirabic Sales by Type
5.3 Americas Vaccin Antirabic Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccin Antirabic Sales by Region
6.1.1 APAC Vaccin Antirabic Sales by Region (2018-2023)
6.1.2 APAC Vaccin Antirabic Revenue by Region (2018-2023)
6.2 APAC Vaccin Antirabic Sales by Type
6.3 APAC Vaccin Antirabic Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccin Antirabic by Country
7.1.1 Europe Vaccin Antirabic Sales by Country (2018-2023)
7.1.2 Europe Vaccin Antirabic Revenue by Country (2018-2023)
7.2 Europe Vaccin Antirabic Sales by Type
7.3 Europe Vaccin Antirabic Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccin Antirabic by Country
8.1.1 Middle East & Africa Vaccin Antirabic Sales by Country (2018-2023)
8.1.2 Middle East & Africa Vaccin Antirabic Revenue by Country (2018-2023)
8.2 Middle East & Africa Vaccin Antirabic Sales by Type
8.3 Middle East & Africa Vaccin Antirabic Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccin Antirabic
10.3 Manufacturing Process Analysis of Vaccin Antirabic
10.4 Industry Chain Structure of Vaccin Antirabic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccin Antirabic Distributors
11.3 Vaccin Antirabic Customer
12 WORLD FORECAST REVIEW FOR VACCIN ANTIRABIC BY GEOGRAPHIC REGION
12.1 Global Vaccin Antirabic Market Size Forecast by Region
12.1.1 Global Vaccin Antirabic Forecast by Region (2024-2029)
12.1.2 Global Vaccin Antirabic Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vaccin Antirabic Forecast by Type
12.7 Global Vaccin Antirabic Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Vaccin Antirabic Product Portfolios and Specifications
13.1.3 GSK Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Vaccin Antirabic Product Portfolios and Specifications
13.2.3 Sanofi Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Chengda
13.3.1 Chengda Company Information
13.3.2 Chengda Vaccin Antirabic Product Portfolios and Specifications
13.3.3 Chengda Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Chengda Main Business Overview
13.3.5 Chengda Latest Developments
13.4 Yisheng
13.4.1 Yisheng Company Information
13.4.2 Yisheng Vaccin Antirabic Product Portfolios and Specifications
13.4.3 Yisheng Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Yisheng Main Business Overview
13.4.5 Yisheng Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Vaccin Antirabic Product Portfolios and Specifications
13.5.3 Merck Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 VACN
13.6.1 VACN Company Information
13.6.2 VACN Vaccin Antirabic Product Portfolios and Specifications
13.6.3 VACN Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 VACN Main Business Overview
13.6.5 VACN Latest Developments
13.7 Changsheng
13.7.1 Changsheng Company Information
13.7.2 Changsheng Vaccin Antirabic Product Portfolios and Specifications
13.7.3 Changsheng Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Changsheng Main Business Overview
13.7.5 Changsheng Latest Developments
13.8 BCHT
13.8.1 BCHT Company Information
13.8.2 BCHT Vaccin Antirabic Product Portfolios and Specifications
13.8.3 BCHT Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BCHT Main Business Overview
13.8.5 BCHT Latest Developments
13.9 Hissen
13.9.1 Hissen Company Information
13.9.2 Hissen Vaccin Antirabic Product Portfolios and Specifications
13.9.3 Hissen Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Hissen Main Business Overview
13.9.5 Hissen Latest Developments
13.10 Zhongke Biological
13.10.1 Zhongke Biological Company Information
13.10.2 Zhongke Biological Vaccin Antirabic Product Portfolios and Specifications
13.10.3 Zhongke Biological Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Zhongke Biological Main Business Overview
13.10.5 Zhongke Biological Latest Developments
13.11 Ningbo Rongan Biological Pharmaceutical
13.11.1 Ningbo Rongan Biological Pharmaceutical Company Information
13.11.2 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product Portfolios and Specifications
13.11.3 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Ningbo Rongan Biological Pharmaceutical Main Business Overview
13.11.5 Ningbo Rongan Biological Pharmaceutical Latest Developments
13.12 Guangzhou Nuocheng Biological
13.12.1 Guangzhou Nuocheng Biological Company Information
13.12.2 Guangzhou Nuocheng Biological Vaccin Antirabic Product Portfolios and Specifications
13.12.3 Guangzhou Nuocheng Biological Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Guangzhou Nuocheng Biological Main Business Overview
13.12.5 Guangzhou Nuocheng Biological Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccin Antirabic Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Vaccin Antirabic by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Vaccin Antirabic by Country/Region, 2018, 2022 & 2029
2.2 Vaccin Antirabic Segment by Type
2.2.1 Gopher Kidney Cell Vaccine
2.2.2 Freeze-Dried Vero Cell Vaccine
2.2.3 Common Vero Cell Vaccines
2.2.4 Human Diploid Vaccine
2.3 Vaccin Antirabic Sales by Type
2.3.1 Global Vaccin Antirabic Sales Market Share by Type (2018-2023)
2.3.2 Global Vaccin Antirabic Revenue and Market Share by Type (2018-2023)
2.3.3 Global Vaccin Antirabic Sale Price by Type (2018-2023)
2.4 Vaccin Antirabic Segment by Application
2.4.1 Pre-exposure Prophylaxis
2.4.2 After Exposure Prophylaxis
2.4.3 Additional Doses
2.5 Vaccin Antirabic Sales by Application
2.5.1 Global Vaccin Antirabic Sale Market Share by Application (2018-2023)
2.5.2 Global Vaccin Antirabic Revenue and Market Share by Application (2018-2023)
2.5.3 Global Vaccin Antirabic Sale Price by Application (2018-2023)
3 GLOBAL VACCIN ANTIRABIC BY COMPANY
3.1 Global Vaccin Antirabic Breakdown Data by Company
3.1.1 Global Vaccin Antirabic Annual Sales by Company (2018-2023)
3.1.2 Global Vaccin Antirabic Sales Market Share by Company (2018-2023)
3.2 Global Vaccin Antirabic Annual Revenue by Company (2018-2023)
3.2.1 Global Vaccin Antirabic Revenue by Company (2018-2023)
3.2.2 Global Vaccin Antirabic Revenue Market Share by Company (2018-2023)
3.3 Global Vaccin Antirabic Sale Price by Company
3.4 Key Manufacturers Vaccin Antirabic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccin Antirabic Product Location Distribution
3.4.2 Players Vaccin Antirabic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VACCIN ANTIRABIC BY GEOGRAPHIC REGION
4.1 World Historic Vaccin Antirabic Market Size by Geographic Region (2018-2023)
4.1.1 Global Vaccin Antirabic Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Vaccin Antirabic Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Vaccin Antirabic Market Size by Country/Region (2018-2023)
4.2.1 Global Vaccin Antirabic Annual Sales by Country/Region (2018-2023)
4.2.2 Global Vaccin Antirabic Annual Revenue by Country/Region (2018-2023)
4.3 Americas Vaccin Antirabic Sales Growth
4.4 APAC Vaccin Antirabic Sales Growth
4.5 Europe Vaccin Antirabic Sales Growth
4.6 Middle East & Africa Vaccin Antirabic Sales Growth
5 AMERICAS
5.1 Americas Vaccin Antirabic Sales by Country
5.1.1 Americas Vaccin Antirabic Sales by Country (2018-2023)
5.1.2 Americas Vaccin Antirabic Revenue by Country (2018-2023)
5.2 Americas Vaccin Antirabic Sales by Type
5.3 Americas Vaccin Antirabic Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccin Antirabic Sales by Region
6.1.1 APAC Vaccin Antirabic Sales by Region (2018-2023)
6.1.2 APAC Vaccin Antirabic Revenue by Region (2018-2023)
6.2 APAC Vaccin Antirabic Sales by Type
6.3 APAC Vaccin Antirabic Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccin Antirabic by Country
7.1.1 Europe Vaccin Antirabic Sales by Country (2018-2023)
7.1.2 Europe Vaccin Antirabic Revenue by Country (2018-2023)
7.2 Europe Vaccin Antirabic Sales by Type
7.3 Europe Vaccin Antirabic Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccin Antirabic by Country
8.1.1 Middle East & Africa Vaccin Antirabic Sales by Country (2018-2023)
8.1.2 Middle East & Africa Vaccin Antirabic Revenue by Country (2018-2023)
8.2 Middle East & Africa Vaccin Antirabic Sales by Type
8.3 Middle East & Africa Vaccin Antirabic Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccin Antirabic
10.3 Manufacturing Process Analysis of Vaccin Antirabic
10.4 Industry Chain Structure of Vaccin Antirabic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccin Antirabic Distributors
11.3 Vaccin Antirabic Customer
12 WORLD FORECAST REVIEW FOR VACCIN ANTIRABIC BY GEOGRAPHIC REGION
12.1 Global Vaccin Antirabic Market Size Forecast by Region
12.1.1 Global Vaccin Antirabic Forecast by Region (2024-2029)
12.1.2 Global Vaccin Antirabic Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vaccin Antirabic Forecast by Type
12.7 Global Vaccin Antirabic Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Vaccin Antirabic Product Portfolios and Specifications
13.1.3 GSK Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Vaccin Antirabic Product Portfolios and Specifications
13.2.3 Sanofi Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Chengda
13.3.1 Chengda Company Information
13.3.2 Chengda Vaccin Antirabic Product Portfolios and Specifications
13.3.3 Chengda Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Chengda Main Business Overview
13.3.5 Chengda Latest Developments
13.4 Yisheng
13.4.1 Yisheng Company Information
13.4.2 Yisheng Vaccin Antirabic Product Portfolios and Specifications
13.4.3 Yisheng Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Yisheng Main Business Overview
13.4.5 Yisheng Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Vaccin Antirabic Product Portfolios and Specifications
13.5.3 Merck Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 VACN
13.6.1 VACN Company Information
13.6.2 VACN Vaccin Antirabic Product Portfolios and Specifications
13.6.3 VACN Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 VACN Main Business Overview
13.6.5 VACN Latest Developments
13.7 Changsheng
13.7.1 Changsheng Company Information
13.7.2 Changsheng Vaccin Antirabic Product Portfolios and Specifications
13.7.3 Changsheng Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Changsheng Main Business Overview
13.7.5 Changsheng Latest Developments
13.8 BCHT
13.8.1 BCHT Company Information
13.8.2 BCHT Vaccin Antirabic Product Portfolios and Specifications
13.8.3 BCHT Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BCHT Main Business Overview
13.8.5 BCHT Latest Developments
13.9 Hissen
13.9.1 Hissen Company Information
13.9.2 Hissen Vaccin Antirabic Product Portfolios and Specifications
13.9.3 Hissen Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Hissen Main Business Overview
13.9.5 Hissen Latest Developments
13.10 Zhongke Biological
13.10.1 Zhongke Biological Company Information
13.10.2 Zhongke Biological Vaccin Antirabic Product Portfolios and Specifications
13.10.3 Zhongke Biological Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Zhongke Biological Main Business Overview
13.10.5 Zhongke Biological Latest Developments
13.11 Ningbo Rongan Biological Pharmaceutical
13.11.1 Ningbo Rongan Biological Pharmaceutical Company Information
13.11.2 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product Portfolios and Specifications
13.11.3 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Ningbo Rongan Biological Pharmaceutical Main Business Overview
13.11.5 Ningbo Rongan Biological Pharmaceutical Latest Developments
13.12 Guangzhou Nuocheng Biological
13.12.1 Guangzhou Nuocheng Biological Company Information
13.12.2 Guangzhou Nuocheng Biological Vaccin Antirabic Product Portfolios and Specifications
13.12.3 Guangzhou Nuocheng Biological Vaccin Antirabic Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Guangzhou Nuocheng Biological Main Business Overview
13.12.5 Guangzhou Nuocheng Biological Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaccin Antirabic Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Vaccin Antirabic Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Gopher Kidney Cell Vaccine
Table 4. Major Players of Freeze-Dried Vero Cell Vaccine
Table 5. Major Players of Common Vero Cell Vaccines
Table 6. Major Players of Human Diploid Vaccine
Table 7. Global Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 8. Global Vaccin Antirabic Sales Market Share by Type (2018-2023)
Table 9. Global Vaccin Antirabic Revenue by Type (2018-2023) & ($ million)
Table 10. Global Vaccin Antirabic Revenue Market Share by Type (2018-2023)
Table 11. Global Vaccin Antirabic Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 13. Global Vaccin Antirabic Sales Market Share by Application (2018-2023)
Table 14. Global Vaccin Antirabic Revenue by Application (2018-2023)
Table 15. Global Vaccin Antirabic Revenue Market Share by Application (2018-2023)
Table 16. Global Vaccin Antirabic Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Vaccin Antirabic Sales by Company (2018-2023) & (K Units)
Table 18. Global Vaccin Antirabic Sales Market Share by Company (2018-2023)
Table 19. Global Vaccin Antirabic Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Vaccin Antirabic Revenue Market Share by Company (2018-2023)
Table 21. Global Vaccin Antirabic Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Vaccin Antirabic Producing Area Distribution and Sales Area
Table 23. Players Vaccin Antirabic Products Offered
Table 24. Vaccin Antirabic Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Vaccin Antirabic Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Vaccin Antirabic Sales Market Share Geographic Region (2018-2023)
Table 29. Global Vaccin Antirabic Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Vaccin Antirabic Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Vaccin Antirabic Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Vaccin Antirabic Sales Market Share by Country/Region (2018-2023)
Table 33. Global Vaccin Antirabic Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Vaccin Antirabic Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 36. Americas Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 37. Americas Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 39. Americas Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 40. Americas Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 41. APAC Vaccin Antirabic Sales by Region (2018-2023) & (K Units)
Table 42. APAC Vaccin Antirabic Sales Market Share by Region (2018-2023)
Table 43. APAC Vaccin Antirabic Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Vaccin Antirabic Revenue Market Share by Region (2018-2023)
Table 45. APAC Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 46. APAC Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 47. Europe Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 48. Europe Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 49. Europe Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 51. Europe Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 52. Europe Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Vaccin Antirabic
Table 60. Key Market Challenges & Risks of Vaccin Antirabic
Table 61. Key Industry Trends of Vaccin Antirabic
Table 62. Vaccin Antirabic Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Vaccin Antirabic Distributors List
Table 65. Vaccin Antirabic Customer List
Table 66. Global Vaccin Antirabic Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Vaccin Antirabic Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Vaccin Antirabic Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Vaccin Antirabic Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Vaccin Antirabic Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Vaccin Antirabic Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Vaccin Antirabic Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Vaccin Antirabic Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. GSK Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 81. GSK Vaccin Antirabic Product Portfolios and Specifications
Table 82. GSK Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. GSK Main Business
Table 84. GSK Latest Developments
Table 85. Sanofi Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 86. Sanofi Vaccin Antirabic Product Portfolios and Specifications
Table 87. Sanofi Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Sanofi Main Business
Table 89. Sanofi Latest Developments
Table 90. Chengda Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 91. Chengda Vaccin Antirabic Product Portfolios and Specifications
Table 92. Chengda Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Chengda Main Business
Table 94. Chengda Latest Developments
Table 95. Yisheng Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 96. Yisheng Vaccin Antirabic Product Portfolios and Specifications
Table 97. Yisheng Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Yisheng Main Business
Table 99. Yisheng Latest Developments
Table 100. Merck Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck Vaccin Antirabic Product Portfolios and Specifications
Table 102. Merck Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. VACN Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 106. VACN Vaccin Antirabic Product Portfolios and Specifications
Table 107. VACN Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. VACN Main Business
Table 109. VACN Latest Developments
Table 110. Changsheng Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 111. Changsheng Vaccin Antirabic Product Portfolios and Specifications
Table 112. Changsheng Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Changsheng Main Business
Table 114. Changsheng Latest Developments
Table 115. BCHT Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 116. BCHT Vaccin Antirabic Product Portfolios and Specifications
Table 117. BCHT Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. BCHT Main Business
Table 119. BCHT Latest Developments
Table 120. Hissen Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 121. Hissen Vaccin Antirabic Product Portfolios and Specifications
Table 122. Hissen Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Hissen Main Business
Table 124. Hissen Latest Developments
Table 125. Zhongke Biological Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 126. Zhongke Biological Vaccin Antirabic Product Portfolios and Specifications
Table 127. Zhongke Biological Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Zhongke Biological Main Business
Table 129. Zhongke Biological Latest Developments
Table 130. Ningbo Rongan Biological Pharmaceutical Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 131. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product Portfolios and Specifications
Table 132. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Ningbo Rongan Biological Pharmaceutical Main Business
Table 134. Ningbo Rongan Biological Pharmaceutical Latest Developments
Table 135. Guangzhou Nuocheng Biological Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 136. Guangzhou Nuocheng Biological Vaccin Antirabic Product Portfolios and Specifications
Table 137. Guangzhou Nuocheng Biological Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Guangzhou Nuocheng Biological Main Business
Table 139. Guangzhou Nuocheng Biological Latest Developments
Table 1. Vaccin Antirabic Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Vaccin Antirabic Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Gopher Kidney Cell Vaccine
Table 4. Major Players of Freeze-Dried Vero Cell Vaccine
Table 5. Major Players of Common Vero Cell Vaccines
Table 6. Major Players of Human Diploid Vaccine
Table 7. Global Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 8. Global Vaccin Antirabic Sales Market Share by Type (2018-2023)
Table 9. Global Vaccin Antirabic Revenue by Type (2018-2023) & ($ million)
Table 10. Global Vaccin Antirabic Revenue Market Share by Type (2018-2023)
Table 11. Global Vaccin Antirabic Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 13. Global Vaccin Antirabic Sales Market Share by Application (2018-2023)
Table 14. Global Vaccin Antirabic Revenue by Application (2018-2023)
Table 15. Global Vaccin Antirabic Revenue Market Share by Application (2018-2023)
Table 16. Global Vaccin Antirabic Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Vaccin Antirabic Sales by Company (2018-2023) & (K Units)
Table 18. Global Vaccin Antirabic Sales Market Share by Company (2018-2023)
Table 19. Global Vaccin Antirabic Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Vaccin Antirabic Revenue Market Share by Company (2018-2023)
Table 21. Global Vaccin Antirabic Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Vaccin Antirabic Producing Area Distribution and Sales Area
Table 23. Players Vaccin Antirabic Products Offered
Table 24. Vaccin Antirabic Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Vaccin Antirabic Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Vaccin Antirabic Sales Market Share Geographic Region (2018-2023)
Table 29. Global Vaccin Antirabic Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Vaccin Antirabic Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Vaccin Antirabic Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Vaccin Antirabic Sales Market Share by Country/Region (2018-2023)
Table 33. Global Vaccin Antirabic Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Vaccin Antirabic Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 36. Americas Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 37. Americas Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 39. Americas Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 40. Americas Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 41. APAC Vaccin Antirabic Sales by Region (2018-2023) & (K Units)
Table 42. APAC Vaccin Antirabic Sales Market Share by Region (2018-2023)
Table 43. APAC Vaccin Antirabic Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Vaccin Antirabic Revenue Market Share by Region (2018-2023)
Table 45. APAC Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 46. APAC Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 47. Europe Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 48. Europe Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 49. Europe Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 51. Europe Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 52. Europe Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Vaccin Antirabic Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Vaccin Antirabic Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Vaccin Antirabic Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Vaccin Antirabic Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Vaccin Antirabic Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Vaccin Antirabic Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Vaccin Antirabic
Table 60. Key Market Challenges & Risks of Vaccin Antirabic
Table 61. Key Industry Trends of Vaccin Antirabic
Table 62. Vaccin Antirabic Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Vaccin Antirabic Distributors List
Table 65. Vaccin Antirabic Customer List
Table 66. Global Vaccin Antirabic Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Vaccin Antirabic Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Vaccin Antirabic Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Vaccin Antirabic Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Vaccin Antirabic Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Vaccin Antirabic Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Vaccin Antirabic Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Vaccin Antirabic Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Vaccin Antirabic Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Vaccin Antirabic Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. GSK Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 81. GSK Vaccin Antirabic Product Portfolios and Specifications
Table 82. GSK Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. GSK Main Business
Table 84. GSK Latest Developments
Table 85. Sanofi Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 86. Sanofi Vaccin Antirabic Product Portfolios and Specifications
Table 87. Sanofi Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Sanofi Main Business
Table 89. Sanofi Latest Developments
Table 90. Chengda Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 91. Chengda Vaccin Antirabic Product Portfolios and Specifications
Table 92. Chengda Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Chengda Main Business
Table 94. Chengda Latest Developments
Table 95. Yisheng Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 96. Yisheng Vaccin Antirabic Product Portfolios and Specifications
Table 97. Yisheng Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Yisheng Main Business
Table 99. Yisheng Latest Developments
Table 100. Merck Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck Vaccin Antirabic Product Portfolios and Specifications
Table 102. Merck Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. VACN Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 106. VACN Vaccin Antirabic Product Portfolios and Specifications
Table 107. VACN Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. VACN Main Business
Table 109. VACN Latest Developments
Table 110. Changsheng Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 111. Changsheng Vaccin Antirabic Product Portfolios and Specifications
Table 112. Changsheng Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Changsheng Main Business
Table 114. Changsheng Latest Developments
Table 115. BCHT Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 116. BCHT Vaccin Antirabic Product Portfolios and Specifications
Table 117. BCHT Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. BCHT Main Business
Table 119. BCHT Latest Developments
Table 120. Hissen Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 121. Hissen Vaccin Antirabic Product Portfolios and Specifications
Table 122. Hissen Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Hissen Main Business
Table 124. Hissen Latest Developments
Table 125. Zhongke Biological Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 126. Zhongke Biological Vaccin Antirabic Product Portfolios and Specifications
Table 127. Zhongke Biological Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Zhongke Biological Main Business
Table 129. Zhongke Biological Latest Developments
Table 130. Ningbo Rongan Biological Pharmaceutical Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 131. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product Portfolios and Specifications
Table 132. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Ningbo Rongan Biological Pharmaceutical Main Business
Table 134. Ningbo Rongan Biological Pharmaceutical Latest Developments
Table 135. Guangzhou Nuocheng Biological Basic Information, Vaccin Antirabic Manufacturing Base, Sales Area and Its Competitors
Table 136. Guangzhou Nuocheng Biological Vaccin Antirabic Product Portfolios and Specifications
Table 137. Guangzhou Nuocheng Biological Vaccin Antirabic Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Guangzhou Nuocheng Biological Main Business
Table 139. Guangzhou Nuocheng Biological Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaccin Antirabic
Figure 2. Vaccin Antirabic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccin Antirabic Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Vaccin Antirabic Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Vaccin Antirabic Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Gopher Kidney Cell Vaccine
Figure 10. Product Picture of Freeze-Dried Vero Cell Vaccine
Figure 11. Product Picture of Common Vero Cell Vaccines
Figure 12. Product Picture of Human Diploid Vaccine
Figure 13. Global Vaccin Antirabic Sales Market Share by Type in 2022
Figure 14. Global Vaccin Antirabic Revenue Market Share by Type (2018-2023)
Figure 15. Vaccin Antirabic Consumed in Pre-exposure Prophylaxis
Figure 16. Global Vaccin Antirabic Market: Pre-exposure Prophylaxis (2018-2023) & (K Units)
Figure 17. Vaccin Antirabic Consumed in After Exposure Prophylaxis
Figure 18. Global Vaccin Antirabic Market: After Exposure Prophylaxis (2018-2023) & (K Units)
Figure 19. Vaccin Antirabic Consumed in Additional Doses
Figure 20. Global Vaccin Antirabic Market: Additional Doses (2018-2023) & (K Units)
Figure 21. Global Vaccin Antirabic Sales Market Share by Application (2022)
Figure 22. Global Vaccin Antirabic Revenue Market Share by Application in 2022
Figure 23. Vaccin Antirabic Sales Market by Company in 2022 (K Units)
Figure 24. Global Vaccin Antirabic Sales Market Share by Company in 2022
Figure 25. Vaccin Antirabic Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Vaccin Antirabic Revenue Market Share by Company in 2022
Figure 27. Global Vaccin Antirabic Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Vaccin Antirabic Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 30. Americas Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 31. APAC Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 32. APAC Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 33. Europe Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 34. Europe Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 37. Americas Vaccin Antirabic Sales Market Share by Country in 2022
Figure 38. Americas Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 39. Americas Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 40. Americas Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 41. United States Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Vaccin Antirabic Sales Market Share by Region in 2022
Figure 46. APAC Vaccin Antirabic Revenue Market Share by Regions in 2022
Figure 47. APAC Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 48. APAC Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 49. China Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Vaccin Antirabic Sales Market Share by Country in 2022
Figure 57. Europe Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 58. Europe Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 59. Europe Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 60. Germany Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Vaccin Antirabic Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 69. Egypt Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Vaccin Antirabic in 2022
Figure 75. Manufacturing Process Analysis of Vaccin Antirabic
Figure 76. Industry Chain Structure of Vaccin Antirabic
Figure 77. Channels of Distribution
Figure 78. Global Vaccin Antirabic Sales Market Forecast by Region (2024-2029)
Figure 79. Global Vaccin Antirabic Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Vaccin Antirabic Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Vaccin Antirabic Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Vaccin Antirabic Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Vaccin Antirabic Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Vaccin Antirabic
Figure 2. Vaccin Antirabic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccin Antirabic Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Vaccin Antirabic Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Vaccin Antirabic Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Gopher Kidney Cell Vaccine
Figure 10. Product Picture of Freeze-Dried Vero Cell Vaccine
Figure 11. Product Picture of Common Vero Cell Vaccines
Figure 12. Product Picture of Human Diploid Vaccine
Figure 13. Global Vaccin Antirabic Sales Market Share by Type in 2022
Figure 14. Global Vaccin Antirabic Revenue Market Share by Type (2018-2023)
Figure 15. Vaccin Antirabic Consumed in Pre-exposure Prophylaxis
Figure 16. Global Vaccin Antirabic Market: Pre-exposure Prophylaxis (2018-2023) & (K Units)
Figure 17. Vaccin Antirabic Consumed in After Exposure Prophylaxis
Figure 18. Global Vaccin Antirabic Market: After Exposure Prophylaxis (2018-2023) & (K Units)
Figure 19. Vaccin Antirabic Consumed in Additional Doses
Figure 20. Global Vaccin Antirabic Market: Additional Doses (2018-2023) & (K Units)
Figure 21. Global Vaccin Antirabic Sales Market Share by Application (2022)
Figure 22. Global Vaccin Antirabic Revenue Market Share by Application in 2022
Figure 23. Vaccin Antirabic Sales Market by Company in 2022 (K Units)
Figure 24. Global Vaccin Antirabic Sales Market Share by Company in 2022
Figure 25. Vaccin Antirabic Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Vaccin Antirabic Revenue Market Share by Company in 2022
Figure 27. Global Vaccin Antirabic Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Vaccin Antirabic Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 30. Americas Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 31. APAC Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 32. APAC Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 33. Europe Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 34. Europe Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Vaccin Antirabic Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Vaccin Antirabic Revenue 2018-2023 ($ Millions)
Figure 37. Americas Vaccin Antirabic Sales Market Share by Country in 2022
Figure 38. Americas Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 39. Americas Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 40. Americas Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 41. United States Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Vaccin Antirabic Sales Market Share by Region in 2022
Figure 46. APAC Vaccin Antirabic Revenue Market Share by Regions in 2022
Figure 47. APAC Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 48. APAC Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 49. China Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Vaccin Antirabic Sales Market Share by Country in 2022
Figure 57. Europe Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 58. Europe Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 59. Europe Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 60. Germany Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Vaccin Antirabic Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Vaccin Antirabic Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Vaccin Antirabic Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Vaccin Antirabic Sales Market Share by Application (2018-2023)
Figure 69. Egypt Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Vaccin Antirabic Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Vaccin Antirabic in 2022
Figure 75. Manufacturing Process Analysis of Vaccin Antirabic
Figure 76. Industry Chain Structure of Vaccin Antirabic
Figure 77. Channels of Distribution
Figure 78. Global Vaccin Antirabic Sales Market Forecast by Region (2024-2029)
Figure 79. Global Vaccin Antirabic Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Vaccin Antirabic Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Vaccin Antirabic Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Vaccin Antirabic Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Vaccin Antirabic Revenue Market Share Forecast by Application (2024-2029)
